MARK2 and neoplasm: Janku et al. measured B-Raf protooncogene, serine/threonine kinase (BRAF) mutations in ctDNA from formalin-fixed paraffin-embedded tumour or plasma samples [60], derived from advanced cancer or malignant histiocytosis with known BRAFV600 status.